Apogee Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
APGE Nasdaq 2834 www.apogeetherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Apogee Therapeutics, Inc.

Apogee Therapeutics (APGE) Is Up 17.8% After $403 Million Follow-On Tied To Zumilokibart Data - Mar 27th, 2026 6:16 pm
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million - Mar 26th, 2026 2:01 pm
Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors - Mar 26th, 2026 9:53 am
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering - Mar 24th, 2026 7:53 pm
APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy - Mar 24th, 2026 8:26 am
How Apogee, Up 20%, Plans To Take On Rival Regeneron's Eczema Drug - Mar 23rd, 2026 2:06 pm
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering - Mar 23rd, 2026 2:01 pm
Sector Update: Health Care Stocks Advance Late Afternoon - Mar 23rd, 2026 1:54 pm
Top Midday Stories: Trump Orders 5-Day Postponement of Strikes on Iranian Energy Sites; JPMorgan Launches $8 Billion Junk-Bond Sale for EA Buyout - Mar 23rd, 2026 9:26 am
Apogee Therapeutics Highlights 52-Week Zumi Data, Targets 3- to 6-Month Dosing in AD - Mar 23rd, 2026 8:12 am
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday - Mar 23rd, 2026 7:12 am
Exchange-Traded Funds, Equity Futures Gain Pre-Bell Monday as Trump Declares 5-Day Pause in Iran Energy Attacks - Mar 23rd, 2026 6:57 am
Apogee strengthens case for longer-lasting eczema drug - Mar 23rd, 2026 6:15 am
Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis - Mar 23rd, 2026 4:30 am
Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026 - Mar 22nd, 2026 5:51 pm
A Look At Apogee Therapeutics (APGE) Valuation After Recent Share Price Weakness - Mar 22nd, 2026 12:02 pm
Block upgraded, Starbucks downgraded: Wall Street's top analyst calls - Mar 18th, 2026 7:34 am
VR Adviser Adds Over 1 Million Savara Shares - Mar 15th, 2026 8:59 am
Wedbush Raises Price Target on Apogee Therapeutics (APGE) - Mar 10th, 2026 6:04 am
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing - Mar 4th, 2026 9:11 am